Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI could help pick the right chemo for pancreatic cancer patients

NCT ID NCT06320717

First seen May 06, 2026 · Last updated May 20, 2026 · Updated 4 times

Summary

This study collects blood and tumor tissue from 100 people with pancreatic cancer who are about to receive standard chemotherapy. Researchers will use artificial intelligence to look for biomarkers that might predict which treatment works best for each person. The goal is to make it easier for doctors to choose the right chemotherapy for future patients based on their unique biology.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Good Samaritan University Hospital

    RECRUITING

    West Islip, New York, 11795, United States

    Contact Phone: •••-•••-••••

    Contact

  • Roswell Park Comprehensive Cancer Center

    RECRUITING

    Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.